Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine
Reference23 articles.
1. SARS-CoV-2 variants, vaccines, and host immunity;Mistry;Front Immunol,2021
2. Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study;Dalla Costa;Neurol Sci,2020
3. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis;Louapre;JAMA Neurol,2020
4. Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study;Achiron;J Neuroimmunol,2021
5. Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:17562864211012835.